-
Senesco Finalizes Agreement with Mayo Clinic to Study SNS01-T in Multiple Myeloma
Wednesday, August 24, 2011 - 9:02am | 185Senesco Technologies (NYSE: SNT) today announced that it has finalized a clinical trial agreement with Mayo Clinic in Rochester, MN to study SNS01-T, the Company's lead therapeutic candidate for the treatment of multiple myeloma. Mayo Clinic is a not-for-profit medical practice and medical...
-
Pre-Market Losers; United Therapeutics Down 21%
Wednesday, August 24, 2011 - 8:53am | 78United Therapeutics (NASDAQ: UTHR) -21.25% after being downgraded to Neutral by JP Morgan. American Eagle Outfitters (NYSE: AEO) -7.06% on lower than expected earnings and guidance. Vonage Holdings (NYSE: VG) -6.15% after gaining 9% yesterday. Human Genome Sciences (NASDAQ: HGSI) -5.18% after...
-
Deutsche Bank Downgrades United Therapeutics To Hold
Wednesday, August 24, 2011 - 8:47am | 72According to Deutsche Bank, United Therapeutics (NASDAQ: UTHR) is downgraded to Hold. Deutsche Bank said that this morning United Therapeutics announced that the combination trial Freedom - C(2) for Oral Remodulin did not hit primary endpoint. “We expect stock to remain weak due to this news. We...
-
SIGA Awarded a $7.7M Grant for the Development of Antiviral Drugs for Arenaviruses
Wednesday, August 24, 2011 - 8:29am | 47SIGA Technologies, Inc. (Nasdaq: SIGA) announced today that it has been awarded a $7.7 million grant from the National Institutes of Health to develop an antiviral drug for treating and preventing Lassa fever and other hemorrhagic fevers of Arenavirus origin.
-
JP Morgan Downgrades UTHR To Neutral, Lowers PT To $55
Wednesday, August 24, 2011 - 8:24am | 28JP Morgan has downgraded United Therapeutics (NASDAQ: UTHR) from Overweight to Neutral and has lowered the price target from $75 to $55.
-
Benzinga's Top Downgrades
Wednesday, August 24, 2011 - 7:49am | 129Morgan Keegan downgraded Abbott Laboratories (NYSE: ABT) from “outperform” to “market perform.” ABT's shares closed at $50.51 yesterday. Abbott Laboratories' trailing-twelve-month ROA is 8.03%. Pacific Sunwear of California Inc (NASDAQ: PSUN) was downgraded by Oppenheimer from "outperform" to "...
-
Financial Breakfast for August 24, 2011
Wednesday, August 24, 2011 - 7:42am | 521This is your Benzinga news summary and traders' outlook for Wednesday, August 24, 2011, covering headlines from overnight and Wednesday's pre-market session. Today in domestic pre-market trading, U.S equity futures are trading lower. At last check, Dow futures are down about 75 points and the U.S...
-
Deutsche Bank Downgrades United Therapeutics To Hold, $53 PT
Wednesday, August 24, 2011 - 7:09am | 25Deutsche Bank has downgraded United Therapeutics (NASDAQ: UTHR) from Buy to Hold and maintains its $53 price target.
-
PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Wednesday, August 24, 2011 - 6:45am | 143Pharmasset, Inc. (Nasdaq: VRUS) has received fast track designation from the U.S. Food and Drug Administration (FDA) for PSI-938 for the treatment of chronic hepatitis C virus (HCV) infection. PSI-938 is an oral guanosine nucleotide analog polymerase inhibitor of HCV. In March 2011, Pharmasset...
-
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
Wednesday, August 24, 2011 - 6:40am | 225United Therapeutics Corporation (NASDAQ: UTHR) announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with...
-
CEL-SCI Announces Exclusive Sales, Marketing and Distribution Agreement for Its Investigational Cancer Therapy Multikine for Argentina and Venezuela
Tuesday, August 23, 2011 - 10:16am | 155CEL-SCI Corporation (NYSE: CVM) today announced that it has entered into an exclusive Sales, Marketing and Distribution agreement with IDC-GP Pharm LLC under which CEL-SCI has granted IDC-GP Pharm an exclusive license to market and distribute the Company's investigational cancer therapy, Multikine...
-
Notable Call Options Activity in Sangamo BioSciences
Tuesday, August 23, 2011 - 10:12am | 109Shares of Sangamo BioSciences (NASDAQ: SGMO) are higher on the session by 3.42%, currently trading at $4.84. The stock has been moving largely lower over the past three months and is currently trading below the 50-day average. Options traders are focusing on calls today. A short while ago the...
-
UPDATE: Bank of America Lowers PT on Seattle Genetics from $18 to $17
Tuesday, August 23, 2011 - 9:58am | 102Bank of America has published a research report on Seattle Genetics (NASDAQ: SGEN) lowering the price target. In the report, Bank of America wrote, "All in, our PO is lowered by $1 to $17, driven by the lower pricing. We see potential for upside to our estimates over the next 6-12 months based on...
-
Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS™ in CD30-Positive Non-Hodgkin Lymphoma
Tuesday, August 23, 2011 - 9:00am | 190Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that it has initiated a phase II clinical trial of ADCETRIS™ (brentuximab vedotin) for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less...
-
Brean Murray Carret & Co. Initiates Coverage On HGSI
Tuesday, August 23, 2011 - 8:17am | 109Brean Murray Carret & Co. are initiating coverage on Human Genome Sciences (NASDAQ: HGSI) with a Buy rating and a price target set at $22. Says Brean Murray Carret &Co., in the report, “ The company's key driver is Benlysta, a novel IV therapeutic now approved as a chronic therapy to treat...